Dow Jones -- Swiss biotech company Actelion Ltd. said Monday its experimental sleeping pill almorexant met its main target in a two week late-stage trial, but noted that certain "safety observations" were made that need to be analyzed further, raising concerns over the drug's long-term potential.
